Clinical trials
catalyst calendar across sponsors →Studies where GRAL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 4 observational
Held by 10 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, AQR CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, D. E. Shaw & Co., Inc., Verition Fund Management LLC, +5 more) · FINRA short interest 15.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Galleri® in the Medicare Population.NCT05673018Incidence rates of stage IV cancersNon-randomized · Open-label · Screening | Not applicable | Recruiting | Device: Multi-Cancer Early Detection Test (Galleri®) | Cancer | 50,000 | Sep 2030 | ≤ 1,503 d | 2026-05-22 |
| Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical TrialNCT05611632incidence of stage III and IV cancers diagnosed in the intervention arm as compared with the control armRandomized · Triple-masked · Screening | Not applicable | Active, not recruiting | Device: Multi-cancer early detection test (Galleri test) | Cancer | 142,318 | 2026-06-12actual | — | 2026-07-10 |
| PATHFINDER 2: A Multi-Cancer Early Detection StudyNCT05155605Safety: Number and type of invasive procedures performed in participants with a cancer signal detected by the multi-cancer early detection (MCED) test and no cancer diagnosis at the time of diagnostic resolution (i.e., false positive test result).Open-label · Screening | Not applicable | Active, not recruiting | Device: Multi-Cancer Early Detection Test | Early Detection of Cancer, Cancer | 35,883 | 2026-02-11actual | — | 2026-05-14 |
| The Galleri® Community Research ProgramNCT06603259observationalQuality of data retrieved from participants who have received the Galleri test | — | Enrolling by invitation | — | Data Collection | 250 | Dec 2025 | — | 2024-09-19 |
| REFLECTION: A Clinical Practice Learning Program for Galleri®NCT05205967observationalTo describe signal detection and cancer detection within and across sites among participants who opt to receive Galleri® in a real world setting. | — | Active, not recruiting | Other: MCED, SOC | Early Detection of Cancer, Cancer | 14,633 | 2025-09-30actual | — | 2025-11-26 |
| The Circulating Cell-free Genome Atlas StudyNCT02889978observationalTo collect and study clinically-annotated biospecimens, specifically peripheral blood and contemporary tumor tissue when available, to characterize cfNA profiles from deep sequencing and to estimate the population heterogeneity in two arms of the study. | — | Unknown status | — | Neoplasms, Cancer | 15,254 | Mar 2024 | — | 2023-09-13 |
| The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer TypesNCT03085888observationalTo evaluate the performance of the pre-specified GRAIL Test to detect invasive cancers (including hematologic malignancies). | — | Completed | — | Neoplasms, Cancer | 99,481 | 2022-06-30actual | — | 2024-09-20 |
| Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical PracticeNCT04241796Per participant count of the number and types of diagnostic tests required to achieve diagnostic resolution following a "signal detected" multi-cancer early detection test result.Open-label · Screening | Not applicable | Completed | Device: Multi-Cancer Early Detection Test | Cancer | 6,662 | 2021-12-01actual | — | 2022-10-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19